Anzurstobart

• CAT Number: I040388
• CAS Number: 2543693-10-1
• Purity: ≥95%

Anzurstobart(CAT: I040388) is a fully human IgG1κ monoclonal antibody targeting IL‑23p19, a critical subunit of the pro-inflammatory cytokine interleukin-23. By selectively neutralizing IL‑23 signaling, it inhibits downstream activation of Th17 cells and reduces expression of key inflammatory mediators such as IL‑17A and IL‑22. Anzurstobart is currently in clinical development for moderate-to-severe plaque psoriasis, showing promising efficacy in reducing lesion severity and achieving rapid skin clearance. It also demonstrates a favorable safety and tolerability profile. Supplied at high purity, Anzurstobart is ideally suited for research in dermatology, autoimmune inflammation, and Th17-mediated disease mechanisms.